Literature DB >> 19025127

Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response.

Tom Eirik Mollnes1, Dorte Christiansen, Ole-Lars Brekke, Terje Espevik.   

Abstract

Pattern recognition is an essential event in innate immunity. Complement and Toll-like receptors (TLR), including the CD14 molecule, are two important upstream components of the innate immune system, recognizing exogenous structures as well as endogenous ligands. They act partly independent in the inflammatory network, but also have several cross-talk mechanisms which are under current investigation. Complement is an essential part of innate immunity protecting the host against infection. However, it is a double-edged sword since inappropriate activation may damage the host. Uncontrolled systemic activation of complement, as seen in severe sepsis, may contribute to the breakdown of homeostatic mechanisms leading to the irreversible state of septic shock. Complement inhibition is promising for protection of lethal experimental sepsis, but clinical studies are missing. Lipopolysaccharide (LPS) has been implicated in the pathogenesis of gram-negative sepsis by inducing synthesis of pro-inflammatory cytokines through binding to CD14 and the TLR4/MD-2 complex. Neutralization of LPS or blocking of CD14 has been effective in preventing LPS-induced lethal shock in animal studies, but results from clinical studies have been disappointing, as for most other therapeutic strategies. Based on some recently published data and further pilot data obtained in our laboratory, we hypothesize that inhibition of complement combined with neutralization of CD14 may attenuate the uncontrolled inflammatory reaction which leads to breakdown of homeostasis during sepsis. We further postulate this regimen as an approach for efficient inhibition of the initial innate recognition, exogenous as well as endogenous, to prevent downstream activation of the inflammatory reaction in general.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19025127

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  25 in total

1.  Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

Authors:  Anne-Catherine Raby; Chantal S Colmont; Ann Kift-Morgan; Jörg Köhl; Matthias Eberl; Donald Fraser; Nicholas Topley; Mario O Labéta
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

2.  Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans.

Authors:  Andreas Barratt-Due; Ebbe Billmann Thorgersen; Julie Katrine Lindstad; Anne Pharo; Olga Lissina; John D Lambris; Miles A Nunn; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

3.  Single nucleotide polymorphisms of IL-13 and CD14 genes in allergic rhinitis: a meta-analysis.

Authors:  Min-Li Chen; Hua Zhao; Qiu-Pin Huang; Zheng-Fu Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-23       Impact factor: 2.503

4.  Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice.

Authors:  Markus Huber-Lang; Andreas Barratt-Due; Søren E Pischke; Øystein Sandanger; Per H Nilsson; Miles A Nunn; Stephanie Denk; Wilhelm Gaus; Terje Espevik; Tom E Mollnes
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

5.  Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.

Authors:  Robert Silasi-Mansat; Hua Zhu; Narcis I Popescu; Glenn Peer; Georgia Sfyroera; Paola Magotti; Lacramioara Ivanciu; Cristina Lupu; Tom E Mollnes; Fletcher B Taylor; Gary Kinasewitz; John D Lambris; Florea Lupu
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

6.  Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood.

Authors:  Ebbe Billmann Thorgersen; Anne Pharo; Karin Haverson; Anne K Axelsen; Peter Gaustad; Girish J Kotwal; Georgia Sfyroera; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

7.  Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.

Authors:  Arunan S Vamadevan; Masayuki Fukata; Elizabeth T Arnold; Lisa S Thomas; David Hsu; Maria T Abreu
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

8.  Systemic CD14 inhibition attenuates organ inflammation in porcine Escherichia coli sepsis.

Authors:  Ebbe Billmann Thorgersen; Søren Erik Pischke; Andreas Barratt-Due; Hilde Fure; Julie Katrine Lindstad; Anne Pharo; Bernt Christian Hellerud; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

9.  CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs.

Authors:  Ebbe Billmann Thorgersen; Bernt Christian Hellerud; Erik Waage Nielsen; Andreas Barratt-Due; Hilde Fure; Julie Katrine Lindstad; Anne Pharo; Erik Fosse; Tor Inge Tønnessen; Harald Thidemann Johansen; Albert Castellheim; Tom Eirik Mollnes
Journal:  FASEB J       Date:  2009-10-19       Impact factor: 5.191

10.  Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation.

Authors:  Mateja Mancek-Keber; Helena Gradisar; Melania Iñigo Pestaña; Guillermo Martinez de Tejada; Roman Jerala
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.